Corvus Pharmaceuticals (CRVS) Cash from Operations (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Cash from Operations of 10374000.0 for Q1 2026, down 25.55% year-over-year from 13933738.95 in Q1 2025, and down 12.87% quarter-over-quarter from 9191000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Cash from Operations (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 10374000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 25.55% year-over-year to 10374000.0; the TTM figure through Mar 2026 stood at 34908000.0 (down 22.36% YoY), while the FY2025 annual figure was 32797000.0, down 29.0% from the prior year.
- Cash from Operations for Q1 2026 stood at 10374000.0, down from 9191000.0 in the prior quarter.
- The five-year high for Cash from Operations was 5157000.0 in Q1 2024, with the low at 10374000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 6424000.0 (2022), against an average of 7032529.41.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations surged 51.59% in 2022, then plunged 63.83% in 2024.
- Corvus Pharmaceuticals' Cash from Operations stood at 7547000.0 in 2022, then jumped by 31.54% to 5167000.0 in 2023, then tumbled by 63.83% to 8465000.0 in 2024, then fell by 8.58% to 9191000.0 in 2025, then declined by 12.87% to 10374000.0 in 2026.
- Business Quant data shows CRVS's Cash from Operations at 10374000.0 in Q1 2026, 9191000.0 in Q4 2025, and 9566000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -15.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.40 Mn |
| Jun 30, 2026 | -15.40 Mn |
| Mar 31, 2026 | -10.37 Mn |
| Mar 31, 2026 | -10.37 Mn |
| Dec 31, 2025 | -9.19 Mn |
| Dec 31, 2025 | -9.19 Mn |
| Sep 30, 2025 | -9.57 Mn |
| Sep 30, 2025 | -9.57 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Mar 31, 2025 | -8.26 Mn |
| Mar 31, 2025 | -8.26 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Sep 30, 2024 | -6.32 Mn |
| Sep 30, 2024 | -6.32 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -5.16 Mn |
| Mar 31, 2024 | -5.16 Mn |